

## TAT-GluN2B

Cat. No.:	HY-P5281
CAS No.:	1587636-62-1
Molecular Formula:	C <sub>137</sub> H <sub>242</sub> N <sub>62</sub> O <sub>32</sub>
Molecular Weight:	3269.78
Sequence:	Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Lys-Asn-Arg-Asn-Lys-Leu-Arg-Arg-Gln-His-Ser-Tyr
Sequence Shortening:	YGRKKRRQRRRKKNRNKLRRQHSY
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	TAT-GluN2B, a synthetic peptide, is a negative control of Tat-GluN2BCTM (Neuroprotective Agent) <sup>[1]</sup> .
In Vitro	TAT-GluN2BCTM (25 μM, neuronal culture) results in significant reduction of DAPK1 following NMDA treatment, but TAT-GluN2B does not affect DAPK1 level <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TAT-GluN2BCTM (10 mg/kg, i.v.) specifically knocks down DAPK1 in ischemic brain areas and reduces neuronal damage in the MCAo model of focal ischemia in rats, but TAT-GluN2B does not change DAPK1 levels in the brain tissues of either ischemic or contralateral side <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Fan X, et al. Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation. Nat Neurosci. 2014 Mar;17(3):471-80.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA